What Dextran 70 Treats: Main Uses and Benefits

Dextran 70 is commonly used to help manage two distinct domains of symptomatic distress. The primary applications are relevant across acute therapeutic contexts, and it is also used within therapeutic areas involving localized symptomatic relief.

---

Stabilizing Acute Circulatory Deficiency

This substance is applied in clinical settings that involve acute or unstable symptom patterns, specifically addressing symptoms related to systemic imbalance like critically low blood pressure (hypotension) associated with severe blood loss. It is used in conditions associated with acute or disruptive episodes such as major hemorrhage following trauma or significant volume depletion from severe burns. This supportive use is applied to help manage acute symptoms related to circulatory stability and is relevant in contexts involving heightened systemic burden.

“Symptomatic management often focuses on providing support that helps ease the overall symptom burden related to acute circulatory distress.”

It is commonly used across conditions presenting with acute episodes, such as hypovolemia and circulatory shock stemming from volume loss, and provides supportive relief following major surgery or severe traumatic injury.

---

Quick Fact: Relief for Ocular Discomfort

Dextran 70 is considered relevant for easing symptoms related to inflammatory or irritative states on the eye’s surface. It is used when groups of symptoms, including dryness and a gritty feeling, interfere with daily comfort. This application provides supportive relief when symptoms interfere with routine activities and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. NIH StatPearls overview

Eligibility Map: Who can and cannot use Dextran 70 — Official Regulatory Information

Official regulatory documents strictly define the eligibility for intravenous Dextran 70, primarily based on the patient's existing fluid balance, coagulation status, and organ function.

---

Eligibility Scope
Populations for whom use is allowed (as stated in label):
* Adults presenting with hypovolemia or circulatory shock.
* Children (Use may be permitted with dose calculation based on body weight, though efficacy is not sufficiently established).
Populations for whom use is contraindicated:
* Patients with Hypersensitivity to dextrans or excipients.
* Patients with Marked Hemostatic Defects (bleeding disorders).
* Patients with Severe Oliguria or Anuria (very low or no urine output) due to Renal Disease.
* Patients with Marked Cardiac Decompensation or Severe Congestive Heart Failure.
* Pregnancy at Term (close to delivery).

---

Age, Organ Function, and Reproductive Status
Age-related eligibility rules:
* Pediatric Population: Clinical safety and efficacy are not sufficiently established by dedicated studies.
* Older Adults (Geriatrics): Use requires caution due to increased risk of fluid overload and potential concurrent drug use.
Condition-specific eligibility rules:
* Renal Impairment: Contraindicated in severe forms. Use with caution in less severe impairment.
* Pregnancy/Lactation: Contraindicated near term. Use is generally not recommended during pregnancy unless essential.

---

Connection to the overall eligibility profile: Official regulatory documents establish absolute non-eligibility for populations with severe cardiovascular, renal, or coagulation defects where the medication could worsen volume status or bleeding risk. Eligibility for other groups, such as children and older adults, is defined by conditional restrictions or the lack of established data, mandating that the medicine only be used under specific cautions detailed in the label.

Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Dextran 70 as primarily one of pharmacodynamic caution and procedural constraint, rather than pharmacokinetic drug interactions. The section dedicated to interactions in regulatory labeling often states that no drug-drug interactions are known.

---

Official Interaction Statements

• Pharmacodynamic Reinforcement: Caution is required when Dextran 70 is co-administered with drugs known to affect coagulation, such as anticoagulants or antiplatelet agents. This is due to the potential for an additive effect that increases the risk related to bleeding or hemorrhage.
• Mandatory Timing Rule: The regulatory profile mandates the pre-injection of Dextran 1 (hapten dextran) immediately prior to the administration of Dextran 70. This specific timing requirement is necessary to mitigate the risk of severe hypersensitivity reactions.
• Laboratory Test Interference: Dextran 70 may interfere with certain laboratory procedures, including blood typing and cross-matching tests, particularly if blood samples are taken after the infusion has begun. This requires the use of special laboratory processing techniques.

---

Interaction Classifications (High-Level)

Category	Regulatory Status
Drug–Drug Interactions	None known (metabolic/transporter)
Coagulation Agents	Caution due to Additive Effect
Dextran 1	Mandatory Pre-treatment Requirement

This structure reflects the official stance that the primary concerns are related to the substance's effect on blood hemostasis and a required administration step, defining the constraints for its co-administration.

Dextran 70 is a high molecular weight polysaccharide that functions primarily by modifying the osmotic gradient and the physical properties of blood within the intravascular space. The molecule remains confined to the circulation, generating a high colloid osmotic pressure (COP). This osmotic gradient drives a rapid movement of fluid from the interstitial space into the vascular system, resulting in an increase in circulating plasma volume.

The resultant increase in volume subsequently modulates cardiac preload and increases cardiac output. Additionally, Dextran 70 exerts a secondary effect on hemorheology. By binding to the surface of circulating components, including red blood cells and platelets, Dextran 70 induces a negative charge that minimizes cellular aggregation. This action results in a reduction of blood viscosity, which consequently modulates microcirculatory flow dynamics. These combined actions modulate the hemodynamic state by affecting both volume and flow characteristics.

How to Use Dextran 70: Administration Guidelines

Instructions for using Dextran 70 differ based on the product formulation—either an Intravenous (IV) Solution for plasma volume expansion or an Ophthalmic Solution (eye drops). All administration must strictly adhere to the dosing and procedural constraints standardized for each preparation.

---

Administration Routes and Forms

Product Form	Approved Route	Primary Use Context
6% Solution in Dextrose/Saline	Intravenous (IV) Infusion	Acute Volume Replacement
Ophthalmic Solution	Instillation into the Eye	Topical Lubricant (Often Combined)

---

Labeled Dosing and Administration

Intravenous Administration

• Initial Dose: The typical starting dosage for adults is 500 mL to 1000 mL.
• Infusion Rate: The first 10 mL to 20 mL should be infused slowly over several minutes. For non-emergent administration, the rate should not exceed 4 mL per minute.
• Daily Maximum: The total dosage must not exceed 20 mL/kg of body weight (or 1.2 g/kg) during the first 24 hours. Subsequent daily doses should not exceed 10 mL/kg.
• Pediatric Dosing: Recommended initial doses are 10 mL/kg for children and 5 mL/kg for infants.

Ophthalmic Administration

• Dose: Instill 1 or 2 drops into the affected eye(s) as needed or as directed.
• Procedure: To prevent contamination, the tip of the dropper must not touch the eye or any surface. If using multiple topical eye medications, space the administrations at least five minutes apart.

---

Procedural Constraints

Both forms require visual inspection before use. The IV solution must be clear and free of particles. The use protocol is highly procedural, setting precise maximum cumulative dose limits and infusion rate constraints for IV use, alongside specific techniques for topical application.

Dextran 70: Overview of Research Studies

Research has explored the role of Dextran 70 in settings of acute fluid volume loss, often used in conditions such as shock or severe trauma. The available evidence primarily comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies monitored outcomes related to circulatory status, such as changes in fluid levels and blood pressure, during the initial hours of treatment.

Studies describe patterns observed regarding how Dextran 70 was associated with volume expansion when studied against other fluids. Findings indicate whether studies described differences in the use of additional blood or fluid products during the initial treatment interval.

---

Research has also explored Dextran 70 use related to the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE), especially in patients undergoing major surgery. Trials monitored the measured incidence of blood clot formation during the immediate post-operative recovery period, with studies reporting patterns in the event rates in the Dextran 70 groups compared to groups receiving alternative agents.

---

What is Still Uncertain About Dextran 70 Research

Long-term effects are not fully established regarding sustained recovery or organ function, as follow-up durations were limited in most trials. Comparative evidence is lacking for several modern treatment protocols, meaning that direct comparisons between all treatments are limited.

Subgroup findings are uncertain, especially for special populations like patients with pre-existing conditions or different age groups, as sample sizes were modest in many relevant studies. Furthermore, the overall evidence quality varies across studies, with findings sometimes mixed regarding measured outcomes across different patient subgroups. Research is ongoing, but the existing evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. The comparative effectiveness of different prophylactic methods for prevention of venous thromboembolism after total hip and knee arthroplasty

Common questions about Dextran 70 (FAQ)

---

Q: Is Dextran 70 the same as Dextran 40?

A: Dextran 70 and Dextran 40 are both classified as plasma volume expanders, but they are different preparations. Official drug monographs indicate they are distinguishable by their average molecular weight (size). Dextran 70 has an average molecular weight of approximately 70,000 Daltons, while Dextran 40 is a smaller molecule with a weight around 40,000 Daltons.

---

Q: What is the maximum daily dose for an adult?

A: Official administration guidelines set strict limits on the total dose that may be administered. Regulatory guidelines indicate that the maximum dosage is calculated based on body weight, and limits are set for both the initial 24 hours and subsequent daily doses. A healthcare provider is responsible for monitoring the patient and administering the product according to these limits.

---

Q: How long can I use Dextran 70 eye drops after opening?

A: The official product information specifies a time limit for using the ophthalmic solution after it has been opened for the first time. To maintain the quality and sterility of the product, the official product information indicates the ophthalmic solution is intended to be discarded within a period, typically four weeks, after the first opening.

---

Q: Can Dextran 70 be given to pregnant women?

A: Dextran 70 is classified by the FDA as a Pregnancy Category C drug. Labeling generally advises against use during pregnancy unless the potential benefit is considered necessary by the healthcare provider. Official documents also state that it is specifically contraindicated (prohibited) when the patient is close to delivery.

---

Q: What should I do if I miss a dose of the IV solution?

A: Since Dextran 70 is administered as an intravenous infusion by a healthcare professional in a clinical setting, your dose schedule is managed by the treating team. Any changes to the infusion schedule are managed by the prescribing physician or clinical staff.

---

Q: Why is Dextran 1 required before giving Dextran 70?

A: Official administration instructions mandate the injection of Dextran 1 (hapten dextran) immediately before the administration of Dextran 70. Regulatory documents indicate that this specific pre-treatment is used to help mitigate the risk of severe allergic reactions (anaphylactoid reactions) that have been associated with the initial administration of Dextran 70.

How to Store and Dispose of Dextran 70?

The storage and disposal instructions for Dextran 70 are determined by its formulation (intravenous infusion or ophthalmic solution) to maintain its status as a sterile product.

Official Storage Requirements

Formulation	Required Temperature	Handling and Protection
Intravenous Infusion	Controlled room temperature (15 C to 30 C)	Must be protected from freezing. Do not use if frozen or if solution is discolored or contains precipitate.
Ophthalmic Solution	Controlled room temperature (15 C to 25 C)	Keep out of the sight and reach of children. The cap must be replaced and tightened after each use.

Stability and Disposal

The intravenous infusion is a single-dose product; any unused portion must be discarded immediately after administration. The ophthalmic solution may be used for up to 4 weeks after first opening. In the event of accidental ingestion, immediate medical help or contacting a Poison Control Center is required.